-
1دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
2دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
3دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
4دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
5دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
6دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
7دورية أكاديمية
المؤلفون: Babbe H; Janssen Research and Development, LLC., Spring House, PA 19477., Sundberg TB; Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, Cambridge, MA 02142., Tichenor M; Janssen Research and Development, LLC., San Diego, CA 92121., Seierstad M; Janssen Research and Development, LLC., San Diego, CA 92121., Bacani G; Janssen Research and Development, LLC., San Diego, CA 92121., Berstler J; Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, Cambridge, MA 02142., Chai W; Janssen Research and Development, LLC., San Diego, CA 92121., Chang L; Janssen Research and Development, LLC., San Diego, CA 92121., Chung M; Janssen Research and Development, LLC., San Diego, CA 92121., Coe K; Janssen Research and Development, LLC., San Diego, CA 92121., Collins B; Janssen Research and Development, LLC., San Diego, CA 92121., Finley M; Janssen Research and Development, LLC., Spring House, PA 19477., Guletsky A; Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, Cambridge, MA 02142., Lemke CT; Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, Cambridge, MA 02142., Mak PA; Janssen Research and Development, LLC., San Diego, CA 92121., Mathur A; Janssen Research and Development, LLC., Spring House, PA 19477., Mercado-Marin EV; Janssen Research and Development, LLC., San Diego, CA 92121., Metkar S; Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, Cambridge, MA 02142., Raymond DD; Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, Cambridge, MA 02142., Rives ML; Janssen Research and Development, LLC., San Diego, CA 92121., Rizzolio M; Janssen Research and Development, LLC., San Diego, CA 92121., Shaffer PL; Janssen Research and Development, LLC., Spring House, PA 19477., Smith R; Janssen Research and Development, LLC., San Diego, CA 92121., Smith J; Janssen Research and Development, LLC., San Diego, CA 92121., Steele R; Janssen Research and Development, LLC., Spring House, PA 19477., Steffens H; Janssen Research and Development, LLC., San Diego, CA 92121., Suarez J; Janssen Research and Development, LLC., Spring House, PA 19477., Tian G; Janssen Research and Development, LLC., Spring House, PA 19477., Majewski N; Janssen Research and Development, LLC., Spring House, PA 19477., Volak LP; Janssen Research and Development, LLC., San Diego, CA 92121., Wei J; Janssen Research and Development, LLC., San Diego, CA 92121., Desai PT; Janssen Research and Development, LLC., Spring House, PA 19477., Ong LL; Janssen Research and Development, LLC., Spring House, PA 19477., Koudriakova T; Janssen Research and Development, LLC., San Diego, CA 92121., Goldberg SD; Janssen Research and Development, LLC., San Diego, CA 92121., Hirst G; Janssen Research and Development, LLC., San Diego, CA 92121., Kaushik VK; Broad Institute of MIT and Harvard, Center for the Development of Therapeutics, Cambridge, MA 02142., Ort T; Janssen Research and Development, LLC., Spring House, PA 19477., Seth N; Janssen Research and Development, LLC., Spring House, PA 19477., Graham DB; Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA 02114.; Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114.; Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA 02142., Plevy S; Janssen Research and Development, LLC., Spring House, PA 19477., Venable JD; Janssen Research and Development, LLC., San Diego, CA 92121., Xavier RJ; Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA 02114.; Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114.; Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA 02142., Towne JE; Janssen Research and Development, LLC., San Diego, CA 92121.
المصدر: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2024 Jan 02; Vol. 121 (1), pp. e2307086120. Date of Electronic Publication: 2023 Dec 26.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: National Academy of Sciences Country of Publication: United States NLM ID: 7505876 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1091-6490 (Electronic) Linking ISSN: 00278424 NLM ISO Abbreviation: Proc Natl Acad Sci U S A Subsets: MEDLINE
مواضيع طبية MeSH: Protein Serine-Threonine Kinases*/metabolism , Cyclic AMP Response Element-Binding Protein*/metabolism, Mice ; Humans ; Animals ; Cytokines ; Inflammation/drug therapy ; Protein Isoforms ; Anti-Inflammatory Agents/pharmacology ; Immunity, Innate ; Transcription Factors
-
8دورية أكاديمية
المؤلفون: Volak LP; Janssen Research & Development, LLC, San Diego, California (L.P.V.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.M.D.); Amgen Inc, San Francisco, California (S.H.); Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (D.N.); AbbVie Inc, North Chicago, Illinois (C.P.); AstraZeneca, Cambridge, United Kingdom (A.P.); Roche pRED, Basel, Switzerland (C.R.); GlaxoSmithKline, Stevenage, United Kingdom (P.S.-S.); Genentech, San Francisco, California (D.Z.); and Takeda Development Center Americas, San Diego, California (M.Z.) lvolak@rapportrx.com., Duevel HM; Janssen Research & Development, LLC, San Diego, California (L.P.V.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.M.D.); Amgen Inc, San Francisco, California (S.H.); Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (D.N.); AbbVie Inc, North Chicago, Illinois (C.P.); AstraZeneca, Cambridge, United Kingdom (A.P.); Roche pRED, Basel, Switzerland (C.R.); GlaxoSmithKline, Stevenage, United Kingdom (P.S.-S.); Genentech, San Francisco, California (D.Z.); and Takeda Development Center Americas, San Diego, California (M.Z.)., Humphreys S; Janssen Research & Development, LLC, San Diego, California (L.P.V.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.M.D.); Amgen Inc, San Francisco, California (S.H.); Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (D.N.); AbbVie Inc, North Chicago, Illinois (C.P.); AstraZeneca, Cambridge, United Kingdom (A.P.); Roche pRED, Basel, Switzerland (C.R.); GlaxoSmithKline, Stevenage, United Kingdom (P.S.-S.); Genentech, San Francisco, California (D.Z.); and Takeda Development Center Americas, San Diego, California (M.Z.)., Nettleton D; Janssen Research & Development, LLC, San Diego, California (L.P.V.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.M.D.); Amgen Inc, San Francisco, California (S.H.); Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (D.N.); AbbVie Inc, North Chicago, Illinois (C.P.); AstraZeneca, Cambridge, United Kingdom (A.P.); Roche pRED, Basel, Switzerland (C.R.); GlaxoSmithKline, Stevenage, United Kingdom (P.S.-S.); Genentech, San Francisco, California (D.Z.); and Takeda Development Center Americas, San Diego, California (M.Z.)., Phipps C; Janssen Research & Development, LLC, San Diego, California (L.P.V.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.M.D.); Amgen Inc, San Francisco, California (S.H.); Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (D.N.); AbbVie Inc, North Chicago, Illinois (C.P.); AstraZeneca, Cambridge, United Kingdom (A.P.); Roche pRED, Basel, Switzerland (C.R.); GlaxoSmithKline, Stevenage, United Kingdom (P.S.-S.); Genentech, San Francisco, California (D.Z.); and Takeda Development Center Americas, San Diego, California (M.Z.)., Pike A; Janssen Research & Development, LLC, San Diego, California (L.P.V.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.M.D.); Amgen Inc, San Francisco, California (S.H.); Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (D.N.); AbbVie Inc, North Chicago, Illinois (C.P.); AstraZeneca, Cambridge, United Kingdom (A.P.); Roche pRED, Basel, Switzerland (C.R.); GlaxoSmithKline, Stevenage, United Kingdom (P.S.-S.); Genentech, San Francisco, California (D.Z.); and Takeda Development Center Americas, San Diego, California (M.Z.)., Rynn C; Janssen Research & Development, LLC, San Diego, California (L.P.V.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.M.D.); Amgen Inc, San Francisco, California (S.H.); Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (D.N.); AbbVie Inc, North Chicago, Illinois (C.P.); AstraZeneca, Cambridge, United Kingdom (A.P.); Roche pRED, Basel, Switzerland (C.R.); GlaxoSmithKline, Stevenage, United Kingdom (P.S.-S.); Genentech, San Francisco, California (D.Z.); and Takeda Development Center Americas, San Diego, California (M.Z.)., Scott-Stevens P; Janssen Research & Development, LLC, San Diego, California (L.P.V.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.M.D.); Amgen Inc, San Francisco, California (S.H.); Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (D.N.); AbbVie Inc, North Chicago, Illinois (C.P.); AstraZeneca, Cambridge, United Kingdom (A.P.); Roche pRED, Basel, Switzerland (C.R.); GlaxoSmithKline, Stevenage, United Kingdom (P.S.-S.); Genentech, San Francisco, California (D.Z.); and Takeda Development Center Americas, San Diego, California (M.Z.)., Zhang D; Janssen Research & Development, LLC, San Diego, California (L.P.V.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.M.D.); Amgen Inc, San Francisco, California (S.H.); Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (D.N.); AbbVie Inc, North Chicago, Illinois (C.P.); AstraZeneca, Cambridge, United Kingdom (A.P.); Roche pRED, Basel, Switzerland (C.R.); GlaxoSmithKline, Stevenage, United Kingdom (P.S.-S.); Genentech, San Francisco, California (D.Z.); and Takeda Development Center Americas, San Diego, California (M.Z.)., Zientek M; Janssen Research & Development, LLC, San Diego, California (L.P.V.); The Healthcare Business of Merck KGaA, Darmstadt, Germany (H.M.D.); Amgen Inc, San Francisco, California (S.H.); Novartis Institutes for Biomedical Research, Cambridge, Massachusetts (D.N.); AbbVie Inc, North Chicago, Illinois (C.P.); AstraZeneca, Cambridge, United Kingdom (A.P.); Roche pRED, Basel, Switzerland (C.R.); GlaxoSmithKline, Stevenage, United Kingdom (P.S.-S.); Genentech, San Francisco, California (D.Z.); and Takeda Development Center Americas, San Diego, California (M.Z.).
المصدر: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2023 Jul; Vol. 51 (7), pp. 792-803. Date of Electronic Publication: 2023 Apr 11.
نوع المنشور: Journal Article; Review
بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE
مواضيع طبية MeSH: Drug Discovery* , Ubiquitin-Protein Ligases*, Humans ; Biological Availability ; Solubility
-
9دورية أكاديمية
المؤلفون: Coe KJ; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.) kcoe2@its.jnj.com., Feinstein M; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., Higgins JW; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., Leung P; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., Scott BP; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., Skaptason J; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., Tam Y; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., Volak LP; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., Kinong J; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., Bittner A; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., McAllister H; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., Lim NM; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., Hack M; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.)., Koudriakova T; Janssen Research & Development, L.L.C., San Diego, California (K.J.C., M.F., P.L., B.P.S., L.P.V., H.M., N.M.L., M.H., T.K.); Janssen Research & Development, L.L.C., San Francisco, California (Y.T.), Neurocrine Biosciences, Inc, San Diego, California (J.S.); Pfizer, San Diego, California (J.K.); Turnstone Biologics, La Jolla, California (A.B.); and Trestle Biotherapeutics, San Diego, California (J.W.H.).
المصدر: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2022 Aug; Vol. 50 (8), pp. 1064-1076. Date of Electronic Publication: 2022 Jun 09.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE
مواضيع طبية MeSH: Cytochrome P-450 CYP1A1*/metabolism , Receptors, Aryl Hydrocarbon*/metabolism, Amines ; Animals ; Humans ; Pyrimidines/pharmacology ; Rats ; Thiazoles/pharmacology
-
10دورية أكاديمية
المؤلفون: Petersson C; The Healthcare Business of Merck KGaA, Frankfurter Str. 250, Postcode D50/902, 64293, Darmstadt, Germany. carl.petersson@merckgroup.com., Zhou X; Eli Lilly and Company, Indianapolis, IN, USA., Berghausen J; Novartis, Basel, Switzerland., Cebrian D; GSK, Brentford, UK., Davies M; AstraZeneca, Cambridge, UK., DeMent K; Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA.; XinThera, Inc., San Diego, CA, USA., Eddershaw P; Vertex Pharmaceuticals Incorporated, Boston, MA, USA., Riedmaier AE; Bristol-Myers Squibb, New York, NY, USA., Leblanc AF; AbbVie Inc., North Chicago, IL, USA., Manveski N; F. Hoffman-La Roche Ltd., Basel, Switzerland., Marathe P; Agios Pharmaceuticals, Cambridge, MA, USA., Mavroudis PD; Sanofi, Paris, France., McDougall R; Alnylam Pharmaceuticals, Inc., Cambridge, MA, USA.; Repare Therapeutics, Quebec City, Canada., Parrott N; F. Hoffman-La Roche Ltd., Basel, Switzerland., Reichel A; Bayer AG, Leverkusen, Germany., Rotter C; Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA., Tess D; Pfizer, Inc., New York, NY, USA., Volak LP; Janssen Research and Development, LLC, Raritan, NJ, USA., Xiao G; Sunovion Pharmaceuticals, Inc., Marlborough, MA, USA., Yang Z; Bristol-Myers Squibb, New York, NY, USA., Baker J; Merck and Co., Inc, Kenilworth, NJ, USA.; Blueprint Medicines, Cambridge, MA, USA.
المصدر: The AAPS journal [AAPS J] 2022 Jul 19; Vol. 24 (5), pp. 85. Date of Electronic Publication: 2022 Jul 19.
نوع المنشور: Journal Article; Review
بيانات الدورية: Publisher: American Association of Pharmaceutical Scientists Country of Publication: United States NLM ID: 101223209 Publication Model: Electronic Cited Medium: Internet ISSN: 1550-7416 (Electronic) Linking ISSN: 15507416 NLM ISO Abbreviation: AAPS J Subsets: MEDLINE
مواضيع طبية MeSH: Drug Industry* , Models, Biological*, Humans ; Kinetics ; Pharmaceutical Preparations